ContraFect Corporation (CFRX): Price and Financial Metrics


ContraFect Corporation (CFRX)

Today's Latest Price: $5.06 USD

0.14 (-2.69%)

Updated Jun 2 4:00pm

Add CFRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

CFRX Daily Price Range
CFRX 52-Week Price Range

CFRX Stock Price Chart More Charts


CFRX Price/Volume Stats

Current price $5.06 52-week high $13.40
Prev. close $5.20 52-week low $2.69
Day low $4.97 Volume 244,806
Day high $5.33 Avg. volume 231,527
50-day MA $6.12 Dividend yield N/A
200-day MA $5.70 Market Cap 77.58M

ContraFect Corporation (CFRX) Company Bio


ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. The company was founded in 2008 and is based in Yonkers, New York.


CFRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

CFRX Latest Social Stream


Loading social stream, please wait...

View Full CFRX Social Stream

Latest CFRX News From Around the Web

Below are the latest news stories about CONTRAFECT Corp that investors may wish to consider to help them evaluate CFRX as an investment opportunity.

CFRX: Four Abstracts Published in 30th ECCMID Abstract Book; Financing Overhang Removed as Pfizer Makes Second Investment…

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Four Abstracts Published in 30th ECCMID Abstract Book On May 11, 2020, ContraFect Corp. (NASDAQ:CFRX) announced four abstracts were published in the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) abstract book. Both the on-site and online portion of ECCMID 2020 were cancelled due

Yahoo | May 29, 2020

ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.

ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that Pfizer Inc. (PFE) has entered into a stock purchase agreement with ContraFect pursuant to which Pfizer Inc. has agreed to purchase 674,156 shares of ContraFect’s common stock and a warrant to purchase 505,617 shares of ContraFect’s common stock, for approximately $3.0 million in a private placement transaction that is expected to close on May 27, 2020. The private placement is contingent upon the closing of ContraFect’s public offering previously announced on May 21, 2020, and there can be no assurance as to whether or when the private placement may be completed.

Yahoo | May 26, 2020

The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * AstraZeneca plc (NYSE: AZN) ( announced $1 billion BARDA funding for coronavirus vaccine program) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Cellectis SA (NASDAQ: CLLS) * ChemoCentryx Inc (NASDAQ: CCXI) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cue Biopharma Inc (NASDAQ: CUE) * Fate Therapeutics Inc (NASDAQ: FATE) * Harpoon Therapeutics Inc (NASDAQ: HARP) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Kamada Ltd. (NASDAQ: KMDA) * Minerva Neurosciences Inc (NASDAQ: NERV) * ...

Yahoo | May 22, 2020

ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 11,797,752 shares of its common stock and related warrants to purchase 8,848,314 shares of common stock with an exercise price of $4.90 per share, in exchange for consideration equating to $4.45 for one share of common stock and a warrant to purchase 0.75 shares of common stock. The gross proceeds from the public offering will be approximately $52.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect. All shares in the public offering are to be sold by ContraFect.

Yahoo | May 22, 2020

ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and…

GlobeNewswire | May 21, 2020

Read More 'CFRX' Stories Here

CFRX Price Returns

1-mo -22.98%
3-mo -43.40%
6-mo 46.24%
1-year 23.41%
3-year -59.52%
5-year -88.58%
YTD -18.48%
2019 -59.43%
2018 51.49%
2017 -42.29%
2016 -63.16%
2015 35.71%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7804 seconds.